Richard Porter
Chief Tech/Sci/R&D Officer at UNIQURE N.V.
Net worth: 164 419 $ as of 2024-05-30
Richard Porter active positions
Companies | Position | Start | End |
---|---|---|---|
UNIQURE N.V. | Chief Tech/Sci/R&D Officer | 2023-10-04 | - |
Corporate Officer/Principal | 2022-03-31 | 2023-10-04 |
Career history of Richard Porter
Former positions of Richard Porter
Companies | Position | Start | End |
---|---|---|---|
Therachon AG | Chief Operating Officer | 2016-06-30 | 2019-06-30 |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Chief Tech/Sci/R&D Officer | 2014-02-28 | 2016-07-31 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Corporate Officer/Principal | 2011-08-31 | 2014-01-31 |
Corlieve Therapeutics SAS
Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Corlieve Therapeutics SAS provides neurology services. The company was founded by Richard Porter, Valerie Crepel and Christophe Mulle in November 2019 and is headquartered in Paris, France. | Director/Board Member | 2019-10-31 | - |
Chief Executive Officer | 2019-10-31 | - | |
Founder | 2019-10-31 | - |
Training of Richard Porter
The University of Southampton | Doctorate Degree |
Statistics
International
United Kingdom | 3 |
Switzerland | 3 |
France | 2 |
Operational
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Director/Board Member | 1 |
Sectoral
Health Technology | 3 |
Consumer Services | 2 |
Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
UNIQURE N.V. | Health Technology |
Private companies | 4 |
---|---|
Corlieve Therapeutics SAS
Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Corlieve Therapeutics SAS provides neurology services. The company was founded by Richard Porter, Valerie Crepel and Christophe Mulle in November 2019 and is headquartered in Paris, France. | Health Technology |
Therachon AG | |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Finance |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
- Stock Market
- Insiders
- Richard Porter
- Experience